2025
The Impact and Safety of GLP‐1 Agents and Breast Cancer
Parsons K, Montalvo M, Fischbach N, Taylor M, Alfaro S, Lustberg M. The Impact and Safety of GLP‐1 Agents and Breast Cancer. Cancer Medicine 2025, 14: e70932. PMID: 40552446, PMCID: PMC12186097, DOI: 10.1002/cam4.70932.Peer-Reviewed Original ResearchConceptsBreast cancer patientsGLP-1 receptor agonistsBreast cancerBreast cancer-specific mortalityCancer patientsBreast cancer incidenceBreast cancer ratesWeight management interventionsProportion of breast cancer patientsNon-cancer populationObese post-menopausal womenReceptor agonistsBreast cancer outcomesBreast cancer progressionWeight loss interventionWeight management strategiesEffective weight managementGLP-1Quality of lifeAll-cause mortalityCancer-specific mortalityImprove patient outcomesObesity prevalenceWeb of ScienceCancer incidenceDetection of emergency department patients at risk of dementia through artificial intelligence
Cohen I, Taylor R, Xue H, Faustino I, Festa N, Brandt C, Gao E, Han L, Khasnavis S, Lai J, Mecca A, Sapre A, Young J, Zanchelli M, Hwang U. Detection of emergency department patients at risk of dementia through artificial intelligence. Alzheimer's & Dementia 2025, 21: e70334. PMID: 40457744, PMCID: PMC12130574, DOI: 10.1002/alz.70334.Peer-Reviewed Original ResearchConceptsElectronic health record dataHealth record dataEmergency departmentDetect dementiaDementia detectionYale New Haven HealthRecord dataRisk of dementiaEmergency department patientsBalance detection accuracyDementia algorithmsImprove patient outcomesCare coordinationCare transitionsDementia diagnosisReal-time applicationsClinical decision-makingClinician supportED usePatient safetyProbable dementiaMachine learning algorithmsED workflowED visitsED encountersUpdate on Acute Tubulointerstitial Nephritis: Clinical Features, Immunologic Insights, and Diagnostic and Treatment Approaches
Sahutoglu T, Perazella M. Update on Acute Tubulointerstitial Nephritis: Clinical Features, Immunologic Insights, and Diagnostic and Treatment Approaches. Kidney International Reports 2025, 10: 1643-1656. DOI: 10.1016/j.ekir.2025.03.050.Peer-Reviewed Original ResearchAcute tubulointerstitial nephritisAcute kidney injuryC-reactive proteinAcute kidney diseaseTubulointerstitial nephritisType IV hypersensitivity mechanismKidney diseaseAcute kidney injury etiologyTh2-mediated immune responsesSerum C-reactive proteinTriggered by medicationsTumor necrosis factor (TNF)-aInterleukin (IL)-9Urinary retinol-binding proteinT helper (Th)1T cell polarizationIrreversible kidney damageInflammatory endotypesImprove patient outcomesPrompt diagnosisKidney biopsyT cellsClinical featuresDiagnostic challengeImmune heterogeneityCurrent management of hypertrophic cardiomyopathy
Sikand N, Stendahl J, Sen S, Lampert R, Day S. Current management of hypertrophic cardiomyopathy. The BMJ 2025, 389: e077274. PMID: 40425241, DOI: 10.1136/bmj-2023-077274.Peer-Reviewed Original ResearchConceptsOutflow tract gradientObstructive hypertrophic cardiomyopathyHypertrophic cardiomyopathyAtrial fibrillationLeft ventricular outflow tract gradientNon-obstructive hypertrophic cardiomyopathyManagement of hypertrophic cardiomyopathyRisk of sudden deathCardiac sarcomere genesImplantable cardioverter-defibrillator implantationSeptal reduction therapyNon-obstructive diseaseSymptomatic atrial fibrillationCardiac myosin inhibitorLeft ventricular hypertrophySurgical treatment optionsCardioverter-defibrillator implantationAdvanced heart failureStructural heart conditionsArrhythmic riskCardiac transplantationImprove patient outcomesRhythm controlMedical therapyVentricular hypertrophyImmunological mechanisms and emerging therapeutic targets in alcohol-associated liver disease
Shen H, Liangpunsakul S, Iwakiri Y, Szabo G, Wang H. Immunological mechanisms and emerging therapeutic targets in alcohol-associated liver disease. Cellular & Molecular Immunology 2025, 1-15. PMID: 40399593, DOI: 10.1038/s41423-025-01291-w.Peer-Reviewed Original ResearchAlcohol-associated liver diseaseTherapeutic targetLiver diseaseOptimal treatment strategyAnti-inflammatory therapyNon-parenchymal liver cellsExtra-hepatic organsImprove patient outcomesImmune cellsImmunological mechanismsInflammatory cellsImmunological pathwaysTreatment strategiesInflammatory mediatorsDisease onsetGlobal health challengePatient outcomesNervous systemInflammationAdipose tissueLiver cellsPrecision medicineClinical researchDiseaseHealth challengesMixed Autoimmune Hemolytic Anemia: A Systematic Review of Epidemiology, Clinical Characteristics, Therapies, and Outcomes
Jacobs J, Raza S, Clark L, Stephens L, Allen E, Woo J, Walden R, Villalba C, Tormey C, Stanek C, Adkins B, Bloch E, Booth G. Mixed Autoimmune Hemolytic Anemia: A Systematic Review of Epidemiology, Clinical Characteristics, Therapies, and Outcomes. American Journal Of Hematology 2025 PMID: 40392014, DOI: 10.1002/ajh.27721.Peer-Reviewed Original ResearchAutoimmune hemolytic anemiaDiagnostic criteriaClinical characteristicsMixed autoimmune hemolytic anemiaMultiple lines of therapyComplex hematological disorderLines of therapyNadir hemoglobin levelsReview of epidemiologyInnovative treatment modalitiesEvaluate epidemiological patternsFrequent underlying etiologyCombination therapyHematologic malignanciesImprove patient outcomesFemale predominanceHematological disordersMulticenter studyChronic hemolysisClinical featuresTreatment modalitiesHemoglobin levelsUnderlying etiologyHemolytic anemiaAutoimmune diseasesThe role of microglia in multiple sclerosis: implications for treatment with Bruton’s tyrosine kinase inhibitors
Vermersch P, Airas L, Berger T, Deisenhammer F, Grigoriadis N, Hartung H, Magyari M, Popescu V, Pozzilli C, Pugliatti M, Van Wijmeersch B, Zakaria M, Oreja-Guevara C. The role of microglia in multiple sclerosis: implications for treatment with Bruton’s tyrosine kinase inhibitors. Frontiers In Immunology 2025, 16: 1495529. PMID: 40443664, PMCID: PMC12119304, DOI: 10.3389/fimmu.2025.1495529.Peer-Reviewed Original ResearchConceptsBruton tyrosine kinase inhibitorCentral nervous systemTyrosine kinase inhibitorsBruton's tyrosine kinaseMagnetic resonance imagingPositron emission tomographyMultiple sclerosisMicroglial functionPrimary resident immune cellsTissue repairNeural homeostasisPathogenesis of MSPathophysiology of MSResident immune cellsChronic autoimmune diseaseCentral nervous system developmentInvolvement of microgliaPotential therapeutic strategyModulating microglial functionDisease progression rateImmune surveillanceImprove patient outcomesImmune cellsAutoimmune diseasesProgressive MSNavigating the dynamic landscape of lower-risk MDS: Advances and emerging insights
Mina A, Madanat Y, Abaza Y, Zeidan A. Navigating the dynamic landscape of lower-risk MDS: Advances and emerging insights. Blood Reviews 2025, 101301. PMID: 40450506, DOI: 10.1016/j.blre.2025.101301.Peer-Reviewed Original ResearchAcute myeloid leukemiaLR-MDSErythropoiesis stimulating agentsIncreased risk of transformation to acute myeloid leukemiaMolecular International Prognostic Scoring SystemRisk of transformation to acute myeloid leukemiaTransformation to acute myeloid leukemiaAllogeneic hematopoietic stem cell transplantationInternational Prognostic Scoring SystemHematopoietic stem cell transplantationClonal myeloid malignanciesPrognostic Scoring SystemStem cell transplantationPredominant clinical manifestationLowered riskClinical trial designIneffective hematopoiesisCurative optionMyeloid malignanciesCell transplantationIndolent natureTransfusion supportImprove patient outcomesMyeloid leukemiaClinical manifestationsClinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient Outcomes
Strober B, Bukhalo M, Armstrong A, Pariser D, Kircik L, Johnson B, Montgomery P, Dickerson T. Clinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient Outcomes. Dermatology And Therapy 2025, 15: 1787-1796. PMID: 40349264, PMCID: PMC12126387, DOI: 10.1007/s13555-025-01441-y.Peer-Reviewed Original ResearchImprove patient outcomesPatient outcomesPrescribing behaviorStatistical analysis of concordanceTreatment-as-usual armPhysician prescribing behaviorWeek 4Clinical utilityBiologic drug classesDermal biomarker patchPhysician behaviorAnalysis of patientsManagement of patientsManagement of psoriasisUtilization findingsFisher's exact testHealthcare systemMedication changesInclusion of mindfulnessPhysiciansPsoriasis AreaPatient responseProspective studyLesional skinClinical endpointsAn exploration of trauma-informed care curricula in chiropractic programs: A scoping document analysis protocol
Bensel V, Cupler Z, Poppen O, Joyce J, Allgeier M, Wiles M, Driscoll M, Carbonelli-Cloutier K, Coleman B. An exploration of trauma-informed care curricula in chiropractic programs: A scoping document analysis protocol. PLOS ONE 2025, 20: e0321498. PMID: 40343894, PMCID: PMC12063856, DOI: 10.1371/journal.pone.0321498.Peer-Reviewed Original ResearchConceptsDoctor of chiropractic programTrauma-informed careChiropractic educationChiropractic programsTrauma-informed care trainingTrauma-informed care curriculumRisk of re-traumatizationSubstance Abuse and Mental Health Services AdministrationMental Health Services AdministrationSignificant public health issueHealth Services AdministrationPublic health issueChiropractic careChiropractic trainingImprove patient outcomesEnhance careCare curriculumHealthcare deliveryHealthcare settingsPhysical healthTrauma-exposed patientsServices AdministrationHealth issuesData extractionUnited StatesIdentification of Distinct Biological Groups of Patients With Cryptogenic NORSE via Inflammatory Profiling
Guillemaud M, Chavez M, Kobeissy F, Vezzani A, Jimenez A, Basha M, Batra A, Demeret S, Eka O, Eschbach K, Foreman B, Gaspard N, Gerard E, Gofton T, Haider H, Hantus S, Howe C, Jongeling A, Kalkach-Aparicio M, Kandula P, Kazazian K, Kim M, Lai Y, Marois C, Mellor A, Mohamed W, Morales M, Pimentel C, Ramirez A, Steriade C, Struck A, Taraschenko O, Torcida Sedano N, Wainwright M, Yoo J, Wang K, Navarro V, Hirsch L, Hanin A. Identification of Distinct Biological Groups of Patients With Cryptogenic NORSE via Inflammatory Profiling. Neurology Neuroimmunology & Neuroinflammation 2025, 12: e200403. PMID: 40334176, PMCID: PMC12063244, DOI: 10.1212/nxi.0000000000200403.Peer-Reviewed Original ResearchConceptsCryptogenic new-onset refractory status epilepticusClusters of patientsCytokine profileInflammatory markersNew-onset refractory status epilepticusTarget specific inflammatory pathwaysInitiation of immunotherapyResponse to immunotherapyRefractory status epilepticusPersonalized therapeutic strategiesGroup of patientsStatistically significant elevationTime of administrationProtein pathway analysisInflammatory subgroupsMultiple immunotherapiesDifferential treatment responseRefractory SEC patientsImprove patient outcomesAutoimmune mechanismsImmune dysregulationClinical featuresCytokine levelsAutoimmune processDevelopment of a Central Research Infrastructure that Supports Interdisciplinary Clinical Research and the Adoption of Evidence-Based Practices in the Healthcare Settings
Hrdlicka H, Grevelding P, Rosenblum D, Meyer A, Cullen L, Gilhuly R, Pernigotti D, Corbett J, Morley S, Meise E, Conklin R. Development of a Central Research Infrastructure that Supports Interdisciplinary Clinical Research and the Adoption of Evidence-Based Practices in the Healthcare Settings. Archives Of Physical Medicine And Rehabilitation 2025, 106: e2. DOI: 10.1016/j.apmr.2025.03.008.Peer-Reviewed Original ResearchEvidence-based projectHealthcare professionalsQuality InitiativeAdoption of evidence-based practicesIRB-approved research studyInterdisciplinary clinical researchEvidence-based practiceImprove patient careImprove patient outcomesLevel of trainingSpecialty healthcareClinical researchHealthcare settingsPatient needsPatient careResearch infrastructureNon-academic settingsParticipant enrollmentHealthcare innovationHealthcareStudy designPatient outcomesCo-investigatorsConference abstractsProfessionalsA Tear-Based Approach for Rapid Identification of Bacterial Pathogens in Corneal Ulcers Using Nanopore Sequencing
Dibbs M, Matesva M, Theotoka D, Jayaraj C, Metiku B, Demkowicz P, Heng J, Wang Y, Bakhoum C, Chow J, Bakhoum M. A Tear-Based Approach for Rapid Identification of Bacterial Pathogens in Corneal Ulcers Using Nanopore Sequencing. Translational Vision Science & Technology 2025, 14: 19. PMID: 40244576, PMCID: PMC12013674, DOI: 10.1167/tvst.14.4.19.Peer-Reviewed Original ResearchConceptsCorneal ulcersTear samplesPolymerase chain reactionNanopore sequencingCorneal scrapingsBacterial pathogensTargeted antimicrobial therapyDetection of causative organismsIdentification of bacterial pathogensPolymerase chain reaction amplification of 16S rRNAAmplification of 16S rRNABacterial growthBacterial species identificationContralateral eyeAntimicrobial therapyImprove patient outcomesNext-generation sequencingCausative bacteriaCornealSchirmer stripsCausative organismDetect bacterial pathogensPolymerase chain reaction amplificationTraditional culture methodsCommensal bacteriaPerioperative Point‐of‐Care Ultrasound Utilization in Abdominal Organ Transplantation. Part I: Preoperative and Intraoperative Care
Grell R, Paul J, Gupta K, Chawla N, Deshpande R, De Marchi L, Huang J. Perioperative Point‐of‐Care Ultrasound Utilization in Abdominal Organ Transplantation. Part I: Preoperative and Intraoperative Care. Clinical Transplantation 2025, 39: e70153. PMID: 40245256, PMCID: PMC12005607, DOI: 10.1111/ctr.70153.Peer-Reviewed Original ResearchConceptsAbdominal organ transplantationOrgan transplantationPoint-of-care ultrasoundTransplant anesthesiaIntensive care settingEvidenced-based recommendationsTransesophageal echocardiographyImprove patient outcomesAbdominal organ transplant patientsPoint-of-care ultrasound utilizationVenous congestionFluid managementAdvancement of Transplant AnesthesiaPatient outcomesUltrasound utilizationPoCUSUtilization of point-of-care ultrasoundTransplantationCritical careAnesthesiaImmunotherapy for Renal Cell Carcinoma—What More is to Come?
Yochum Z, Braun D. Immunotherapy for Renal Cell Carcinoma—What More is to Come? Targeted Oncology 2025, 20: 467-483. PMID: 40208564, DOI: 10.1007/s11523-025-01143-7.Peer-Reviewed Original ResearchConceptsICI-based regimensRenal cell carcinomaImmune checkpoint inhibitorsMetastatic renal cell carcinomaVEGFR-TKIsVascular endothelial growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsClinical trialsAnti-PD-1 therapyAntitumor T-cell immunityImprove T-cell activationReceptor tyrosine kinase inhibitorsTreatment of renal cell carcinomaDurability of treatment responseFirst-line therapyPatient outcomesT cell immunityTyrosine kinase inhibitorsFDA-approved agentsT cell activationInnovative treatment strategiesCheckpoint inhibitorsCell carcinomaImprove patient outcomesTumor microenvironmentHER2 testing: evolution and update for a companion diagnostic assay
Robbins C, Bates K, Rimm D. HER2 testing: evolution and update for a companion diagnostic assay. Nature Reviews Clinical Oncology 2025, 22: 408-423. PMID: 40195456, DOI: 10.1038/s41571-025-01016-y.Peer-Reviewed Original ResearchConceptsHER2-targeted therapyHER2 testingHER2-lowSolid tumorsHER2-targeting antibody-drug conjugateHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Accuracy of HER2 testingHER2-low expressionHER2-low tumorsLevels of HER2 expressionTherapeutic decision-makingFluorescence in situ hybridizationAntibody-drug conjugatesTrastuzumab deruxtecanHER2 expressionImprove patient outcomesRNA-based assaysPatient selectionLow levels of HER2 expressionTumor typesBreast cancerQuantitative immunofluorescenceReceptor 2Treatment strategies296 Associated Risk Factors for Extended Length of Stay following Pediatric Tethered Cord Release: An Analysis of 2012 – 2021 NSQIP-Pediatric Database
Hengartner A, Sayeed S, Serrato P, Belkasim S, Sadeghzadeh S, Kundishora A, DiLuna M, Elsamadicy A. 296 Associated Risk Factors for Extended Length of Stay following Pediatric Tethered Cord Release: An Analysis of 2012 – 2021 NSQIP-Pediatric Database. Neurosurgery 2025, 71: 73-73. DOI: 10.1227/neu.0000000000003360_296.Peer-Reviewed Original ResearchNSQIP-Pediatric databaseTethered cord releaseSpinal cordRisk factorsCord releasePediatric patientsSurgical releaseACS NSQIP-Pediatric databaseFactors associated with prolonged hospitalizationMultivariate logistic regression analysisPostoperative hospital LOSTethered spinal cordCardiac risk factorsRetrospective cohort studyHealthcare resource utilizationAssociated risk factorsMultivariate logistic regressionICD-9/10 codesLogistic regression analysisReoperation ratePerioperative complicationsImprove patient outcomesASA classificationPatient demographicsProlonged hospitalization295 Risk Factors Associated With Postoperative Infection following Pediatric Tethered Cord Release: An Analysis of 2012 – 2021 NSQIP-Pediatric Database
Hengartner A, Serrato P, Sayeed S, Belkasim S, Sadeghzadeh S, DiLuna M, Elsamadicy A. 295 Risk Factors Associated With Postoperative Infection following Pediatric Tethered Cord Release: An Analysis of 2012 – 2021 NSQIP-Pediatric Database. Neurosurgery 2025, 71: 73-73. DOI: 10.1227/neu.0000000000003360_295.Peer-Reviewed Original ResearchSurgical site infectionTethered spinal-cord releaseNSQIP-Pediatric databaseCord releaseAdverse eventsPostoperative infectionFactors associated with surgical site infectionACS NSQIP-Pediatric databaseRisk factors associated with postoperative infectionASA classification 3Multivariate logistic regression analysisTethered cord releaseRetrospective cohort analysisStructural CNS abnormalitiesICD-9/10 codesLogistic regression analysisReduce infection ratesPostoperative complicationsASA scoreCNS abnormalitiesImprove patient outcomesPediatric patientsSite infectionPatient demographicsClinical outcomesContemporary understanding of myeloid-derived suppressor cells in the acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) tumor microenvironment
Alhajahjeh A, Stahl M, Kim T, Kewan T, Stempel J, Zeidan A, Bewersdorf J. Contemporary understanding of myeloid-derived suppressor cells in the acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) tumor microenvironment. Expert Review Of Anticancer Therapy 2025, 25: 435-456. PMID: 40122075, DOI: 10.1080/14737140.2025.2483855.Peer-Reviewed Original ResearchMyeloid-derived suppressor cellsAcute myeloid leukemiaMyelodysplastic syndromeSuppressor cellsTumor microenvironmentMyeloid leukemiaEffects of myeloid-derived suppressor cellsTargets myeloid-derived suppressor cellsLeukemic stem cell survivalRisk of leukemia relapseMDSC-targeted therapiesMDSC-mediated immunosuppressionBone marrow nicheStem cell survivalCytokine-mediated pathwaysLeukemia relapseMyeloid diseasesImprove patient outcomesMarrow nichePost-transplantationPreclinical modelsImmunosuppressive propertiesImmunosuppressive componentsFunctional reprogrammingImmune evasionHarnessing Artificial Intelligence for Innovation in Interventional Cardiovascular Care
Aminorroaya A, Biswas D, Pedroso A, Khera R. Harnessing Artificial Intelligence for Innovation in Interventional Cardiovascular Care. Journal Of The Society For Cardiovascular Angiography & Interventions 2025, 4: 102562. PMID: 40230673, PMCID: PMC11993883, DOI: 10.1016/j.jscai.2025.102562.Peer-Reviewed Original ResearchClinical careCommunity-based screening programCare quality outcomesPatient outcomesPatient-focused careHarness artificial intelligenceArtificial intelligencePotential of AIImprove patient outcomesIndividualized clinical careTransform careTransform clinical practiceCardiovascular careScreening programHealth dataQuality outcomesCareClinical workflowClinical tasksAcute coronary syndromeClinical practiceHeart diseaseAI-driven technologiesInterventionAI-enabled
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply